

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2025

or

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission file Number 000-56468

JUSHI HOLDINGS INC.



(Exact name of registrant as specified in its charter)

British Columbia

(State or other jurisdiction of incorporation or organization)

301 Yamato Road, Suite 3250
Boca Raton, FL

(Address of principal executive offices)

(561) 617-9100

(Registrant's telephone number, including
area code)

98-1547061

(IRS Employer
Identification No.)

33431

(Zip Code)

Not Applicable

(Former name, former address and former
fiscal year, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

N/A

Trading Symbol(s)

N/A

Name of each exchange on which registered

N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☒
Emerging growth company	☒		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 30, 2025, the registrant had 196,696,597 subordinate voting shares, no par value per share, no multiple voting shares, no par value per share, no super voting shares, no par value per share, and no preferred shares, no par value per share, outstanding.

JUSHI HOLDINGS INC.

Table of Contents

For the quarterly period ended September 30, 2025

		Page
Part I	FINANCIAL INFORMATION	
Item 1	Financial Statements	
	Condensed Consolidated Balance Sheets	1
	Unaudited Condensed Consolidated Statements of Operations	2
	Unaudited Condensed Consolidated Statements of Changes in Equity (Deficit)	3
	Unaudited Condensed Consolidated Statements of Cash Flows	5
	Notes to the Unaudited Condensed Consolidated Financial Statements	7
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4	Controls and Procedures	32
Part II	OTHER INFORMATION	33
Item 1	Legal Proceedings	33
Item 1A	Risk Factors	33
Item 2	Unregistered Sale of Equity Securities and Use of Proceeds	33
Item 3	Defaults Upon Senior Securities	33
Item 4	Mine Safety Disclosures	33
Item 5	Other Information	33
Item 6	Exhibits	34
Signature		35

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “report”) may contain “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws, including Canadian securities legislation and United States (“U.S.”) securities legislation (collectively, “forward-looking information”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs. All information, other than statements of historical facts, included in this report that address activities, events or developments that the Company expects or anticipates will or may occur in the future constitutes forward-looking information. Forward-looking information is often identified by the words, “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes, among others, information regarding: future business strategy; competitive strengths, goals, expansion and growth of the Company’s business, operations and plans, including new revenue streams; the implementation by the Company of certain product lines; the implementation of certain research and development; the application for additional licenses and the grant of licenses that will be or have been applied for; the expansion or construction of certain facilities; the reduction in the number of our employees; the expansion into additional U.S. and international markets; any potential future legalization of adult use and/or medical marijuana under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future.

Readers are cautioned that forward-looking information is not based on historical facts but instead is based on reasonable assumptions and estimates of the management of the Company at the time they were provided or made and such information involves known and unknown risks, uncertainties, including our ability to continue as a going concern, and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: the limited operating history of the industry and the Company; risks related to managing the growth of the Company including completed, pending or future acquisitions or dispositions, including potential future impairment of goodwill or intangibles acquired and/or post-closing disputes; risks related to the continued performance, expansion and/or optimization of existing operations in California, Illinois, Massachusetts, Nevada, Ohio, Pennsylvania, and Virginia; risks related to the anticipated openings of additional dispensaries or relocation of existing dispensaries subject to licensing approval; the Company’s history of operating losses and negative operating cash flows; increasing competition in the industry; risks inherent in an agricultural business, such as the effects of natural disasters; reliance on the expertise and judgment of senior management of the Company; risks associated with cannabis products manufactured for human consumption including potential product recalls; limited research and data relating to cannabis; constraints on marketing products; risk of litigation; insurance-related risks; public opinion and perception of the cannabis industry; risks related to the economy generally; fraudulent activity by employees, contractors and consultants; risks relating to the Company’s current amount of indebtedness; reliance on key inputs, suppliers and skilled labor, and third party service provider contracts; reliance on manufacturers and contractors; risks of supply shortages or supply chain disruptions; risks relating to pandemics and forces of nature; risks related to the enforceability of contracts; risks related to inflation, the rising cost of capital, and stock market instability; risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; cannabis-related tax risks and challenges from governmental authorities with respect to the Company’s application for Employee Retention Tax Credits (ERC); other governmental and environmental regulation; risks related to proprietary intellectual property and potential infringement by third parties; sales of a significant amount of shares by existing shareholders; the limited market for securities of the Company; risks relating to the need to raise additional capital either through debt or equity financing; costs associated with the Company being a publicly-traded company and a U.S. and Canadian filer; risks related to co-investment with parties with different interests to the Company; conflicts of interest and related party transactions; cybersecurity risks; and risks related to the Company’s critical accounting policies and estimates. Refer to Part I - Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 6, 2025, for more information.

Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on the forward-looking information contained in this report or other forward-looking statements made by the Company. Forward-looking information is provided and made as of the date of this Quarterly Report on Form 10-Q and the Company does not undertake any obligation to revise or update any forward-looking information or statements other than as required by applicable law.

Unless the context requires otherwise, references in this report to “Jushi,” “Company,” “we,” “us” and “our” refer to Jushi Holdings Inc. and our subsidiaries.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

JUSHI HOLDINGS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands of U.S. dollars, except share amounts)

	September 30, 2025 (unaudited)	December 31, 2024
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 23,173	\$ 19,521
Accounts receivable, net	872	1,461
Inventory, net	36,797	36,138
Prepaid expenses and other current assets	7,759	15,030
Total current assets	68,601	72,150
NON-CURRENT ASSETS:		
Property, plant and equipment, net	144,462	144,063
Right-of-use assets - finance leases	59,063	60,627
Other intangible assets, net	94,802	100,472
Goodwill	30,910	30,910
Other non-current assets	31,634	30,273
Restricted cash - non-current	2,225	1,825
Total non-current assets	363,096	368,170
Total assets	\$ 431,697	\$ 440,320
LIABILITIES AND EQUITY (DEFICIT)		
CURRENT LIABILITIES:		
Accounts payable	\$ 20,210	\$ 21,459
Accrued expenses and other current liabilities	29,030	32,786
Income tax payable	771	2,299
Debt, net - current portion (including related party principal amounts of \$15,600 and \$800 as of September 30, 2025 and December 31, 2024, respectively)	48,886	2,758
Finance lease obligations - current	10,291	9,593
Total current liabilities	109,188	68,895
NON-CURRENT LIABILITIES:		
Debt, net - non-current (including related party principal amounts of \$25,667 and \$35,296 as of September 30, 2025 and December 31, 2024, respectively)	155,691	183,449
Finance lease obligations - non-current	53,871	52,742
Derivative liabilities - non-current	9,395	3,128
Unrecognized tax benefits (including interest and penalties of \$36,271 and \$27,839 as of September 30, 2025 and December 31, 2024, respectively)	171,180	143,688
Other liabilities - non-current	33,841	38,653
Total non-current liabilities	423,978	421,660
Total liabilities	533,166	490,555
COMMITMENTS AND CONTINGENCIES (Note 16)		
EQUITY (DEFICIT):		
Common stock, no par value: authorized shares - unlimited; issued and outstanding shares - 196,696,597 and 196,696,597 Subordinate Voting Shares as of September 30, 2025 and December 31, 2024, respectively	—	—
Paid-in capital	510,187	508,386
Accumulated deficit	(611,656)	(558,621)
Total Jushi shareholders' deficit	(101,469)	(50,235)
Non-controlling interests	—	—
Total deficit	(101,469)	(50,235)
Total liabilities and equity (deficit)	\$ 431,697	\$ 440,320

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS***(In thousands of U.S. dollars, except share and per share amounts)*

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
REVENUE, NET	\$ 65,679	\$ 61,611	\$ 194,571	\$ 191,665
COST OF GOODS SOLD	(35,015)	(33,612)	(109,208)	(98,770)
GROSS PROFIT	30,664	27,999	85,363	92,895
OPERATING EXPENSES	28,326	27,819	81,294	80,192
INCOME FROM OPERATIONS	2,338	180	4,069	12,703
OTHER INCOME (EXPENSE):				
Interest expense, net	(10,267)	(9,382)	(30,486)	(27,997)
Fair value gain (loss) on derivatives	(6,325)	2,628	(5,875)	2,840
Other, net	(606)	(477)	6,992	4,186
Total other income (expense), net	(17,198)	(7,231)	(29,369)	(20,971)
LOSS BEFORE INCOME TAX	(14,860)	(7,051)	(25,300)	(8,268)
Income tax expense	(8,829)	(8,965)	(27,735)	(28,041)
NET LOSS	<u>\$ (23,689)</u>	<u>\$ (16,016)</u>	<u>\$ (53,035)</u>	<u>\$ (36,309)</u>
LOSS PER SHARE - BASIC AND DILUTED	<u>\$ (0.12)</u>	<u>\$ (0.08)</u>	<u>\$ (0.27)</u>	<u>\$ (0.19)</u>
Weighted average shares outstanding - basic and diluted	<u>195,196,597</u>	<u>195,165,913</u>	<u>195,196,597</u>	<u>195,145,417</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)
(In thousands of U.S. dollars, except share amounts)

	Nine Months Ended September 30, 2025					
	Subordinate Voting Shares	Paid-In Capital	Accumulated Deficit	Total Jushi Shareholders' Equity (Deficit)	Non- Controlling Interests	Total Equity (Deficit)
Balances - January 1, 2025	196,696,597	\$ 508,386	\$ (558,621)	\$ (50,235)	\$ —	\$ (50,235)
Share-based compensation (including related parties)	—	(307)	—	(307)	—	(307)
Reclassification of warrants	—	1,377	—	1,377	—	1,377
Recognition of non-controlling interest in acquisition	—	—	—	—	300	300
Net loss	—	—	(17,015)	(17,015)	—	(17,015)
Balances - March 31, 2025	196,696,597	\$ 509,456	\$ (575,636)	\$ (66,180)	\$ 300	\$ (65,880)
Share-based compensation (including related parties)	—	374	—	374	—	374
Net loss	—	—	(12,331)	(12,331)	—	(12,331)
Balances - June 30, 2025	196,696,597	\$ 509,830	\$ (587,967)	\$ (78,137)	\$ 300	\$ (77,837)
Share-based compensation (including related parties)	—	\$ 357	\$ —	\$ 357	\$ —	\$ 357
Non-controlling interest paid in acquisition	—	\$ —	\$ —	\$ —	\$ (300)	\$ (300)
Net loss	—	\$ —	\$ (23,689)	\$ (23,689)	\$ —	\$ (23,689)
Balances - September 30, 2025	196,696,597	\$ 510,187	\$ (611,656)	\$ (101,469)	\$ —	\$ (101,469)

JUSHI HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)
(In thousands of U.S. dollars, except share amounts)

	Nine Months Ended September 30, 2024					
	Subordinate Voting Shares	Paid-In Capital	Accumulated Deficit	Total Jushi Shareholders' Equity (Deficit)	Non- Controlling Interests	Total Equity (Deficit)
Balances - January 1, 2024	196,631,598	\$ 503,612	\$ (509,844)	\$ (6,232)	\$ (1,387)	\$ (7,619)
Shares issued upon exercise of stock options	3,333	2	—	2	—	2
Share-based compensation (including related parties)	—	1,524	—	1,524	—	1,524
Issuance of warrants	—	863	—	863	—	863
Net loss	—	—	(18,355)	(18,355)	—	(18,355)
Balances - March 31, 2024	196,634,931	\$ 506,001	\$ (528,199)	\$ (22,198)	\$ (1,387)	\$ (23,585)
Shares issued upon exercise of stock options	8,333	5	—	5	—	5
Share-based compensation (including related parties)	—	347	—	347	—	347
Deconsolidation of Jushi Europe	—	—	—	—	1,387	1,387
Net loss	—	—	(1,938)	(1,938)	—	(1,938)
Balances - June 30, 2024	196,643,264	\$ 506,353	\$ (530,137)	\$ (23,784)	\$ —	\$ (23,784)
Shares issued upon exercise of stock options	53,333	32	—	32	—	32
Share-based compensation (including related parties)	—	1,082	—	1,082	—	1,082
Net loss	—	—	(16,016)	(16,016)	—	(16,016)
Balances - September 30, 2024	196,696,597	\$ 507,467	\$ (546,153)	\$ (38,686)	\$ —	\$ (38,686)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of U.S. dollars)

	Nine Months Ended September 30,	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (53,035)	\$ (36,309)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization, including amounts in cost of goods sold	23,798	21,981
Share-based compensation	424	2,953
Fair value changes in derivatives	5,875	(2,840)
Non-cash interest expense, including amortization of deferred financing costs	7,213	5,062
Deferred income taxes and uncertain tax positions	26,225	25,652
Loss on debt extinguishment	—	362
Gain on asset disposals	(2,712)	(565)
Gain on deconsolidation of Jushi Europe	—	(1,896)
Other non-cash items, net	923	318
Changes in operating assets and liabilities:		
Accounts receivable	(245)	1,662
Inventory	(397)	(9,148)
Prepaid expenses and other current and non-current assets	1,087	(2,109)
Accounts payable, accrued expenses and other current liabilities	2,518	9,292
Net cash flows provided by operating activities	11,674	14,415
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for property, plant and equipment	(13,003)	(2,534)
Investments in intangible assets	(1,099)	—
Proceeds from sale of assets	3,950	2,723
Net cash flows (used in) provided by investing activities	(10,152)	189
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from second lien notes, net of debt discount of \$512	4,608	—
Proceeds from exercise of options	—	39
Payments on promissory notes	—	(6,350)
Proceeds from term loans, net of debt discount of \$970	—	47,530
Payments on acquisition related credit facility	—	(60,125)
Payments of finance leases	(1,768)	(1,661)
Proceeds from mortgage loans, net of issuance cost of \$20	3,473	—
Payments of term loans	(1,213)	—
Payments of loan financing costs	—	(2,357)
Payments of mortgage loans	(444)	(270)
Proceeds from other financing activities	—	1,585
Payments of other financing activities	(1,365)	(1,409)
Net cash flows provided by (used in) financing activities	3,291	(23,018)
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	4,813	(8,414)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	21,346	31,305
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	\$ 26,159	\$ 22,891

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(In thousands of U.S. dollars)

	Nine Months Ended September 30,	
	2025	2024
SUPPLEMENTAL CASH FLOW INFORMATION:		
Cash paid for interest (excluding capitalized interest)	\$ 22,581	\$ 22,798
Cash paid (received) for income taxes	\$ 1,607	\$ (3,829)
NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Capital expenditures	\$ 2,758	\$ 1,944
Right-of-use assets from finance lease liabilities	\$ 3,347	\$ 703
Issuance of promissory notes for acquisitions	\$ 5,909	\$ —
Issuance of second lien notes for settlement of accrued bonus	\$ —	\$ 1,382
Warrants issued for second lien notes	\$ 1,769	\$ —
Financed insurance premiums	\$ 1,459	\$ —
Issuance of second lien notes for debt exchange	\$ —	\$ 4,750
Warrants issued for debt exchange	\$ —	\$ 863
Property, plant and equipment from finance lease liabilities	\$ 991	\$ —
Mortgage loans used for capital expenditures	\$ 507	\$ —
Warrants issued for term loans	\$ —	\$ 6,765

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***1. NATURE OF OPERATIONS**

Jushi Holdings Inc. (the “Company” or “Jushi”) is incorporated under British Columbia’s Business Corporations Act. The Company is a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing in both medical and adult-use markets. As of September 30, 2025, Jushi, through its subsidiaries, owns or manages cannabis operations and/or holds licenses in the adult-use and/or medicinal cannabis marketplace in California, Illinois, Massachusetts, Nevada, Ohio, Pennsylvania and Virginia. The Company’s head office is located at 301 Yamato Road, Suite 3250, Boca Raton, Florida 33431, United States of America, and its registered address is Suite 1700, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2X8, Canada.

The Company is listed on the Canadian Securities Exchange (“CSE”) and trades its subordinate voting shares (“SVS”) under the ticker symbol “JUSH”. The Company’s SVS trade in the United States on the OTCQX® Best Market (“OTCQX”) under the symbol “JUSHF”.

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

The financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes. Actual results could differ materially from those estimates.

In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, of a normal recurring nature, that are necessary to present fairly the financial position, results of operations and cash flows of the Company for the periods, and at the dates, presented. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 6, 2025 (the “2024 Form 10-K”), and also filed on the System for Electronic Document Analysis and Retrieval (“SEDAR”) on March 6, 2025. Consolidated balance sheet information as of December 31, 2024 presented herein is derived from the Company’s audited consolidated financial statements for the year ended December 31, 2024.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2 in the audited consolidated financial statements and notes thereto for the year ended December 31, 2024, which is included in the 2024 Form 10-K. There have been no material changes to the Company’s significant accounting policies.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***Cash, Cash Equivalents and Restricted Cash**

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows:

	September 30, 2025 (unaudited)	December 31, 2024
Cash and cash equivalents	\$ 23,173	\$ 19,521
Restricted cash included in Prepaid expenses and other current assets	761	—
Restricted cash - non-current	2,225	1,825
Cash, cash equivalents and restricted cash	<u>\$ 26,159</u>	<u>\$ 21,346</u>

Recent Accounting Pronouncements*Adoption of New Accounting Standards*

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which requires two primary enhancements of 1) disaggregated information on a reporting entity’s effective tax rate reconciliation, and 2) information on income taxes paid. For public business entities, the new requirement is effective for annual periods beginning after December 15, 2024. The guidance is to be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company adopted this pronouncement on January 1, 2025, which will result in enhanced income tax disclosures in its annual consolidated financial statements.

Accounting Standards Issued But Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, *Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*, which requires an entity to improve disclosures about public business entities’ expenses and to provide more detailed information around the types of expenses included in commonly presented expense captions. Additionally, in January 2025 the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods for fiscal years beginning after December 15, 2027, and can be applied on a prospective basis or on a retrospective basis to all periods presented. Early adoption is permitted. The Company is currently evaluating the effect of these pronouncements on its consolidated financial statements and related disclosures.

In May 2025, the FASB issued ASU 2025-03, *Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity*, which clarifies that when a business that is a VIE is acquired primarily with equity interests, the determination of the accounting acquirer should follow ASC 805 rather than defaulting to the primary beneficiary under ASC 810. ASU 2025-03 is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effect of this pronouncement on its consolidated financial statements and related disclosures.

In July 2025, the FASB issued ASU 2025-05, *Measurement of Credit Losses for Accounts Receivable and Contract Assets*, which provide entities with a practical expedience approach to simplify the estimation of expected credit losses on current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606, *Revenue from Contracts with Customers*, by allowing the assumption that current conditions as of the balance sheet date will not change during the remaining life of the asset. ASU 2025-05 is effective for annual periods beginning after December 15, 2025 and interim periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the effect of this pronouncement on its consolidated financial statements and related disclosures.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***3. INVENTORY, NET**

The components of inventory, net, are as follows:

	September 30, 2025 (unaudited)	December 31, 2024
Cannabis plants	\$ 3,181	\$ 3,621
Harvested cannabis and packaging	8,123	11,290
Total raw materials	11,304	14,911
Work in process	6,898	4,493
Finished goods	18,595	16,734
Total inventory, net	\$ 36,797	\$ 36,138

4. PREPAID EXPENSES AND OTHER CURRENT ASSETS

The components of prepaid expenses and other current assets are as follows:

	September 30, 2025 (unaudited)	December 31, 2024
Prepaid expenses and deposits	\$ 3,728	\$ 3,452
Employee retention credit receivable	1,625	9,181
Assets held for sale	382	611
Other current assets	2,024	1,786
Total prepaid expenses and other current assets	\$ 7,759	\$ 15,030

Employee Retention Credit Receivable

The Coronavirus Aid, Relief, and Economic Security Act, passed in March 2020 and subsequently amended in 2021, allowed eligible employers to take credits on certain amounts of qualified wages if the Company experienced either a full or partial suspension of operations due to COVID related government orders. During the year ended December 31, 2023, the Company, with guidance from a third-party specialist, determined it was entitled to employee retention credit (“ERC”) claims for previous business interruptions related to COVID and filed for such claims with the Internal Revenue Service (“IRS”). As of December 31, 2024, the ERC claims were recorded as deferred income in Accrued expenses and other current liabilities, with an offsetting receivable amount in Prepaid expenses and other current assets within the consolidated balance sheet.

On February 11, 2025, the Company executed an agreement with an unrelated third party to sell certain ERC claims, and received \$5,081 in net cash proceeds on February 14, 2025. If the Company does not receive an ERC claim, in whole or in part, the Company is required to repay a portion of the funds equal to the amount of the rejected claim plus interest of 10% accrued from the date of the agreement through the repayment date. The Company is entitled to receive a portion of any interest paid on its respective ERC claims through the transaction date. The factored claims are included in Other liabilities - non-current within the consolidated balance sheet as of September 30, 2025. Amounts will be recognized in the consolidated statements of operations when the claims are paid by the IRS. As of September 30, 2025, \$1,349 is included in Other liabilities, non-current.

The Company retained \$4,162 of ERC claims. The amount reflected in Prepaid expenses and other current assets as of September 30, 2025, of \$1,625 represents the portion of retained claims that have not yet been refunded by the IRS.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)*

During the three and nine months ended September 30, 2025, the Company received payments on retained claims from the IRS in the amount of \$0 and \$2,474, respectively, plus interest on such amounts, which were recorded in other income (expense), net in the consolidated statements of operations. In addition, during the three and nine months ended September 30, 2025, the IRS paid \$609 and \$3,733, respectively, of factored claims plus interest on such amounts, which is also recorded in other income (expense), net in the consolidated statements of operations.

Assets Held for Sale

As of December 31, 2024, the Company determined that certain assets relating to one of its dispensaries located in Nevada, with total carrying value of \$611, met the criteria to be classified as assets held for sale, and is included in Prepaid expenses and other current assets in the consolidated balance sheet. In May 2025, the Company sold the assets for a net gain of \$2,243, which was recorded in operating expenses in the consolidated statements of operations for the nine months ended September 30, 2025.

5. PROPERTY, PLANT AND EQUIPMENT

The components of property, plant and equipment (“PPE”) are as follows:

	September 30, 2025 (unaudited)	December 31, 2024
Buildings and building components	\$ 90,932	\$ 89,124
Land	12,956	12,956
Leasehold improvements	51,710	47,514
Machinery and equipment	24,392	23,959
Furniture, fixtures and office equipment (including computer)	23,711	22,597
Construction-in-process	7,451	2,533
Total property, plant and equipment - gross	211,152	198,683
Less: Accumulated depreciation	(66,690)	(54,620)
Total property, plant and equipment - net	\$ 144,462	\$ 144,063

Construction-in-process represents assets under construction for manufacturing and retail build-outs not yet ready for use.

Depreciation was \$4,214 and \$4,520 for the three months ended September 30, 2025 and 2024, respectively, and \$13,151 and \$14,403 for the nine months ended September 30, 2025 and 2024, respectively. Interest expense capitalized to PPE totaled \$149 and \$0 for the three months ended September 30, 2025 and 2024, respectively, and \$254 and \$0 for the nine months ended September 30, 2025 and 2024, respectively.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***6. OTHER NON-CURRENT ASSETS**

The components of other non-current assets are as follows:

	September 30, 2025 (unaudited)	December 31, 2024
Operating lease assets	\$ 20,712	\$ 18,114
Indemnification assets	3,137	4,808
Net deferred tax assets	5,288	5,048
Deposits and escrows - properties	1,694	1,723
Deposits - equipment	386	422
Other	417	158
Total other non-current assets	<u>\$ 31,634</u>	<u>\$ 30,273</u>

7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

The components of accrued expenses and other current liabilities are as follows:

	September 30, 2025 (unaudited)	December 31, 2024
Deferred income - ERC ⁽¹⁾	\$ 1,625	\$ 9,181
Goods received not invoiced	2,613	4,366
Accrued employee related expenses and liabilities	6,396	4,095
Operating lease obligations	5,627	4,966
Accrued sales and excise taxes	1,800	1,928
Accrued interest	1,845	1,531
Deferred revenue (loyalty program)	1,417	1,321
Accrued professional and management fees	737	470
Other accrued expenses and current liabilities	6,970	4,928
Total accrued expenses and other current liabilities	<u>\$ 29,030</u>	<u>\$ 32,786</u>

⁽¹⁾ Refer to Note 4 - Prepaid Expenses and Other Current Assets for more information.

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)

8. DEBT

The components of the Company's debt are as follows:

	Effective Interest Rate	Maturity Date	September 30, 2025 (unaudited)	December 31, 2024
Principal amounts:				
Second Lien Notes	17%	December 2026	\$ 85,866	\$ 80,131
Term Loans	26%	September 2026 ⁽¹⁾	47,288	48,500
Acquisition-related promissory notes payable	8% - 13%	October 2025 - April 2027	28,512	22,289
Mortgage loans	6% - 10%	January 2027 - September 2030	32,612	29,054
Total debt subject to scheduled repayments			194,278	179,974
Promissory notes payable to Sammartino ⁽²⁾	10%	September 2024 - September 2026	21,500	21,500
Total debt			215,778	201,474
Less: debt issuance costs and original issue discounts			(11,201)	(15,267)
Total debt, net			\$ 204,577	\$ 186,207
Debt, net - current portion			\$ 48,886	\$ 2,758
Debt, net - non-current portion			\$ 155,691	\$ 183,449

⁽¹⁾ Matures the earlier of (a) January 31, 2027 and (b) the date that is 91 days prior to the final maturity of the Second Lien Notes. The Second Lien Notes are set to mature December 2026.

⁽²⁾ This amount is related to the promissory notes issued to Sammartino Investments LLC ("Sammartino") in connection with the acquisition of Nature's Remedy of Massachusetts, Inc. ("Nature's Remedy") in September 2021. The Company currently has no obligation to pay the principal and interest. See further discussion of the Sammartino Matter in Note 16 - Commitments and Contingencies for more information.

Second Lien Notes

In February 2025, the Company issued US\$3,719 principal amount of 12% second lien notes due 2026 ("Second Lien Notes") and C\$2,000 principal amount of Second Lien Notes. The issuances of the Second Lien Notes were also accompanied by 8,010,626 five-year detached warrants to purchase the Company's subordinate voting shares, no par value per share, in a private placement at a strike price of US\$0.48 per subordinate voting share.

An entity affiliated with James Cacioppo, the Company's Chief Executive Officer, purchased US\$3,719 principal amount of Second Lien Notes for a purchase price of US\$3,347, and received 5,810,938 warrants. Denis Arsenault, a significant equity holder of the Company, purchased C\$2,000 of Second Lien Notes for a purchase price of C\$1,800, and received 2,199,688 warrants.

Term Loans

In July 2024, a syndicate of lenders provided \$48,500 in secured term loans ("Term Loans") to the Company. The Term Loans were issued with a 2% original issue discount, bear interest at a rate of 12.25% per annum and mature the earlier of (a) January 31, 2027 and (b) the date that is 91 days prior to the final maturity of the Second Lien Notes. Beginning August 1, 2025, the Company commenced quarterly principal payments of \$1,213 on the first business day of each calendar quarter with a final payment of \$42,438 at maturity date, plus a 4% exit premium on such amounts. As of September 30, 2025, the remaining principal balance was classified as short-term. The Term Loans' upcoming maturity in September 2026 raises substantial doubt about the Company's ability to continue as a going concern without refinancing.



Given the Company's plan to refinance before maturity and its consistent history of successful refinancing, substantial doubt has been alleviated.

Acquisition-related promissory notes payableStatewide

In February 2025, in connection with an Asset Purchase Agreement with Statewide Property Holdings Ohio, LLC ("Statewide"), the Company issued a promissory note in an aggregate total principal amount of \$2,161 with a stated interest rate of 9% per annum and which matures on or before the one-year anniversary of the third closing date (for the license and inventory assets at the Warren, Ohio dispensary). Following the third closing in June 2025, the promissory note, which provides for full principal and interest payments on the maturity date, will mature in June 2026.

RJK

In February 2025, in connection with an Asset Purchase Agreement with RJK Holdings of Ohio, LLC ("RJK"), the Company issued a promissory note in an aggregate total principal amount of \$4,063 with a stated interest rate of 9% per annum and which matures on or before the one-year anniversary of the third closing date (for the license and inventory assets at the Mansfield, Ohio dispensary). Following the third closing in September 2025, the promissory note, which provides for full principal and interest payments on the maturity date, will mature in September 2026.

Mortgage LoansArlington Mortgage

In December 2021, the Company entered into a \$6,900 mortgage loan agreement (the "Arlington Mortgage"), which is principally secured by the Company's retail property in Arlington, Virginia. The Arlington Mortgage bears a fixed interest rate of 5.875% per annum, payable monthly, and will mature in January 2027.

Dickson City Mortgage

In July 2022, the Company entered into a \$2,800 mortgage loan agreement (the "Dickson City Mortgage"), which is principally secured by the Company's retail property in Dickson City, Pennsylvania. The Dickson City Mortgage matures in July 2027 and bears interest at a variable rate equal to prime rate plus 2%. The interest rate as of September 30, 2025 was 9.5%.

Manassas Mortgage

In April 2023, the Company entered into a \$20,000 mortgage loan agreement (the "Manassas Mortgage"), which is principally secured by the Company's cultivation and manufacturing facility located in Manassas, Virginia (the "Property"). The Manassas Mortgage requires monthly payments and was originally scheduled to mature in April 2028. The interest rate is variable and determined based on the 30-day average secured overnight financing rate plus 3.55%.

In September 2025, the Company executed a modification agreement (the "Modification Agreement") related to the Manassas Mortgage, pursuant to which: (i) the outstanding principal balance was increased by \$4,000, (the "Additional Loan Proceeds"); (ii) the loan's maturity date was extended to September 2030; and (iii) the interest rate floor was lowered from 8.25% to 7.50% (the interest rate remains the average 30-day secured overnight financing rate plus 3.55%). The Manassas Mortgage, as modified, remains principally secured by the Property. In addition, as part of the Modification Agreement, the Company was required to deposit \$761 of the Additional Loan Proceeds into a restricted account, designated for use in fulfilling certain conditions associated with ongoing construction at the Property.

The interest rate as of September 30, 2025 was 7.936%.

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)

Financial Covenants
Term Loans

The Term Loans include a financial covenant that requires the Company to maintain a minimum unrestricted cash balance as of the last day of each calendar month during the term of the Term Loans, with an initial minimum cash balance of \$8,000, subject to certain “step-ups” for succeeding periods. As of September 30, 2025, the Company was in compliance with this financial covenant.

Mortgage loans

The Company’s three mortgage loan agreements contain certain financial and other covenants with which the Company is required to comply. As of September 30, 2025, the Company was in compliance with all financial covenants contained in each of the mortgage loan agreements.

Annual Maturities

As of September 30, 2025, aggregate future scheduled repayments of the Company’s debt were as follows:

	Remainder of the year	2026	2027	2028	2029	Thereafter	Total
Second Lien Notes	\$ —	\$ 85,866	\$ —	\$ —	\$ —	\$ —	\$ 85,866
Term Loans	1,213	46,075	—	—	—	—	47,288
Acquisition-related promissory notes payable	175	6,223	22,114	—	—	—	28,512
Mortgage loans	138	544	9,286	389	427	21,828	32,612
Total debt subject to scheduled repayments	\$ 1,526	\$ 138,708	\$ 31,400	\$ 389	\$ 427	\$ 21,828	\$ 194,278

The above table excludes the maturities of the Company’s promissory notes payable to Sammartino, as the repayment of these notes, if any, would arise in the context of a non-appealable final judgment by a court. Refer to Note 16 - Commitments and Contingencies for more information. Specifically, the promissory notes that were payable to Sammartino are as follows: \$16,500 in 2024 and \$5,000 in 2026. However, these balances are classified as long-term debt since the Company does not expect to repay these amounts within the next 12 months.

Interest Expense

Interest expense, net is comprised of the following:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Interest expense				
Interest and accretion - Second Lien Notes	\$ 3,421	\$ 2,838	\$ 9,914	\$ 8,513
Interest and accretion - Term Loans	2,981	1,832	9,101	1,832
Interest and accretion - Finance lease liabilities	2,602	2,478	7,600	7,550
Interest and accretion - Promissory notes	911	1,043	2,646	3,699
Interest and accretion - Acquisition Facility	—	658	—	4,845
Interest and accretion - Mortgage loans and other financing activities	618	661	1,825	2,037
Capitalized interest	(149)	—	(254)	—
Total interest expense	10,384	9,510	30,832	28,476
Interest income	(117)	(128)	(346)	(479)
Total interest expense, net	\$ 10,267	\$ 9,382	\$ 30,486	\$ 27,997



9. DERIVATIVE LIABILITIES

The following table summarizes the change in the Company's derivative liabilities for the nine months ended September 30, 2025.

	Total Derivative Liabilities (1)
Balance as of January 1, 2025	\$ 3,128
Derivative warrants issued (2)	1,769
Fair value changes	5,875
Reclassification to equity (2)	(1,377)
Balance as of September 30, 2025	\$ 9,395

(1) Refer to Note 10 - Equity for the change in number of warrants during the nine months ended September 30, 2025.

(2) In February 2025, the Company issued 8,010,626 warrants in connection with Second Lien Notes issuances, which were reclassified to equity upon the finalization of the exercise price in March 2025. Refer to Note 8 - Debt for more information.

The Company's derivative liabilities are primarily comprised of derivative warrants ("Derivative Warrants"). These are warrants to purchase SVS of the Company and were issued in connection with the Company's Second Lien Notes and the Term Loans. The Derivative Warrants may be net share settled.

As of September 30, 2025 and December 31, 2024 there were 21,400,000 Derivative Warrants outstanding, which consisted of (i) 2,000,000 warrants with an exercise price of \$2.086 per warrant and expiration date in December 2026, and (ii) 19,400,000 warrants with an exercise price of \$1.00 per warrant and expiration date in July 2029.

Derivative Warrants are considered derivative financial liabilities measured at fair value with all gains or losses recognized in profit or loss as the settlement amount for the Derivative Warrants may be adjusted during certain periods for variables that are not inputs to standard pricing models for forward or option equity contracts, i.e., the "fixed for fixed" criteria under ASC 815-40. The estimated fair value of the Derivative Warrants is measured at the end of each reporting period and an adjustment is reflected in fair value changes in derivatives in the consolidated statements of operations. These are Level 3 recurring fair value measurements. The estimated fair value of the Derivative Warrants was determined using the Black-Scholes model with stock price based on the OTCQX closing price of the Derivative Warrants issue date as of September 30, 2025 and December 31, 2024.

The assumptions used in the fair value calculations as of the balance sheet dates presented include the following:

	September 30, 2025 (unaudited)	December 31, 2024
Stock price per share	\$0.72	\$0.31
Risk-free annual interest rate	3.66% - 3.68%	4.24% - 4.35%
Range of estimated possible exercise price	\$1.00 - \$2.086	\$1.00 - \$2.086
Weighted average volatility	103%	93%
Remaining life	1.2 - 3.8 years	2 - 4.6 years
Forfeiture rate	0%	0%
Expected annual dividend yield	0%	0%

Volatility was estimated by using a weighting of the Company's historical volatility. The risk-free interest rate for the expected life of the Derivative Warrants was based on the yield available on government benchmark bonds with an approximate equivalent remaining term. The expected life is based on the contractual term. If any of the assumptions used in the calculation were to increase or decrease, this could result in a material or significant increase or decrease in the

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)


estimated fair value of the derivative liability. For example, the following table illustrates an increase or decrease in certain significant assumptions as of the balance sheet dates:

	As of September 30, 2025 (unaudited)			As of December 31, 2024		
	Input	Effect of 10% Increase	Effect of 10% Decrease	Input	Effect of 10% Increase	Effect of 10% Decrease
Stock price per share	\$ 0.72	\$ 1,209	\$ (1,186)	\$ 0.31	\$ 440	\$ (427)
Volatility	103 %	770	(841)	93 %	438	(465)

10. EQUITY
Authorized, Issued and Outstanding

The authorized share capital of the Company consists of an unlimited number of SVS, Multiple Voting Shares, Super Voting Shares, and Preferred Shares. As of September 30, 2025, the Company had 196,696,597 SVS issued and outstanding and no Multiple Voting Shares, Super Voting Shares or Preferred Shares issued and outstanding.

Warrants

Each warrant entitles the holder to purchase one SVS. Certain warrants may be net share settled. The following table summarizes the status of warrants and related transactions:

	Non-Derivative (Equity) Warrants	Derivative Liabilities Warrants	Total Number of Warrants	Weighted - Average Exercise Price
Balance as of January 1, 2025	50,518,536	21,400,000	71,918,536	\$ 1.03
Granted ⁽¹⁾	8,210,626	—	8,210,626	\$ 0.48
Balance as of September 30, 2025	58,729,162	21,400,000	80,129,162	\$ 0.98
Exercisable as of September 30, 2025	57,509,162	21,400,000	78,909,162	\$ 0.98

⁽¹⁾ In February 2025, the Company issued 8,010,626 warrants in connection with Second Lien Notes issuances. Refer to Note 8 - Debt for more information.

The grant date fair value of the non-derivative warrants issued was determined using the Black-Scholes option-pricing model. The following assumptions were used for the calculation at date of issuance:

Weighted average stock price	\$0.33
Weighted average expected stock price volatility	91.8%
Expected annual dividend yield	0%
Weighted average expected life of warrants	5.0 years
Weighted average risk-free annual interest rate	4.1%
Weighted average grant date fair value	\$0.22

Share-based Payment Award Plans
Plan summary and description

Under the Company's 2019 Equity Incentive Plan, as amended, (the "2019 Plan"), non-transferable options to purchase SVS and restricted SVS of the Company may be issued to directors, officers, employees, or consultants of the Company. The 2019 Plan authorizes the issuance of up to 15% (plus an additional 2% inducements for hiring employees and senior management) of the number of outstanding shares of common stock (of all classes) of the Company (the "Share

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)


Reserve”). Incentive stock options are limited to the Share Reserve, and the maximum number of incentive awards available for issuance under the 2019 Plan, including additional awards available for certain new hires, was 8,993,836 as of September 30, 2025.

Stock Options

The stock options issued by the Company are options to purchase SVS of the Company. All stock options issued have been issued to directors and employees under the Company’s 2019 Plan. Such options generally expire ten years from the date of grant and generally vest ratably over three years from the grant date. The options generally may be net share settled.

The following table summarizes the status of stock options and related transactions:

	Number of Stock Options	Weighted-Average Per Share Exercise Price
Issued and Outstanding as of January 1, 2025	26,769,419	\$ 0.79
Granted	1,120,000	\$ 0.42
Cancelled/forfeited/expired	(3,444,834)	\$ 0.82
Issued and Outstanding as of September 30, 2025	24,444,585	\$ 0.77
Exercisable as of September 30, 2025	18,507,055	\$ 0.85

The fair value of the stock options granted was determined using the Black-Scholes option-pricing model. The following assumptions were used for the calculation at date of grant:

	Nine Months Ended September 30,	
	2025	2024
Weighted average stock price	\$0.41	\$0.56
Weighted average expected stock price volatility	92.8%	86.9%
Expected annual dividend yield	0%	0%
Weighted average expected life	5.1 years	5.0 years
Weighted average risk-free annual interest rate	3.9%	3.6%
Weighted average grant date fair value	\$0.30	\$0.21

Share-based Compensation Cost

The components of share-based compensation expense, net, are as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Stock options	\$ 261	\$ 982	\$ 187	\$ 2,931
Restricted stock	—	—	—	2
Warrants	96	100	237	20
Total share-based compensation expense, net	\$ 357	\$ 1,082	\$ 424	\$ 2,953

As of September 30, 2025, the Company had \$951 of unrecognized share-based compensation cost related to unvested stock options and warrants, which is expected to be recognized as share-based compensation cost over a weighted average period of 2.0 years.

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)

11. EARNINGS (LOSS) PER SHARE

The reconciliations of the net loss and the weighted average number of shares used in the computations of basic and diluted loss per share are as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Numerator:				
Net loss	\$ (23,689)	\$ (16,016)	\$ (53,035)	\$ (36,309)
Denominator:				
Weighted-average shares of common stock - basic and diluted	195,196,597	195,165,913	195,196,597	195,145,417
Loss per common share:				
Basic and diluted	\$ (0.12)	\$ (0.08)	\$ (0.27)	\$ (0.19)

The following table summarizes weighted average instruments that may, in the future, have a dilutive effect on earnings (loss) per share, but were excluded from consideration in the computation of diluted net loss per share for the three and nine months ended September 30, 2025 and 2024, because the impact of including them would have been anti-dilutive:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Stock options	24,243,562	26,537,311	24,817,114	27,402,967
Warrants (derivative liabilities and equity)	80,129,162	101,726,848	78,392,223	92,766,898
Unvested restricted stock awards	—	1,679	—	1,800
	104,372,724	128,265,838	103,209,337	120,171,665

12. REVENUE

The Company has two revenue streams: (i) retail and (ii) wholesale. The Company's retail revenue is comprised of cannabis sales from its dispensaries. The Company's wholesale revenue is comprised of cannabis sales to its wholesale customers for resale through their dispensaries. Any intercompany revenue and costs are eliminated to arrive at consolidated totals.

The following table summarizes the Company's revenue from external customers, disaggregated by revenue stream:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Retail	\$ 58,774	\$ 55,441	\$ 175,058	\$ 169,802
Wholesale	6,905	6,170	19,513	21,863
Total revenue, net	\$ 65,679	\$ 61,611	\$ 194,571	\$ 191,665



13. OPERATING EXPENSES

The major components of operating expenses are as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Salaries, wages and employee related expenses	\$ 14,315	\$ 14,498	\$ 43,055	\$ 42,837
Depreciation and amortization expenses	4,512	3,985	13,702	11,090
Rent and related expenses	3,184	3,053	9,415	8,928
Professional fees and legal expenses	1,804	1,320	5,584	5,501
Share-based compensation expense	357	1,082	424	2,953
Loss (gain) on asset disposals and lease terminations	306	443	(2,992)	(2,233)
Other expenses ⁽¹⁾	3,848	3,438	12,106	11,116
Total operating expenses	\$ 28,326	\$ 27,819	\$ 81,294	\$ 80,192

⁽¹⁾ Other expenses are primarily comprised of marketing and selling expenses, insurance costs, administrative and licensing fees, software and technology costs, travel, entertainment and other.

14. INCOME TAXES

The following table summarizes the Company's income tax expense and effective tax rates for the three and nine months ended September 30, 2025 and 2024:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Loss before income tax	\$ (14,860)	\$ (7,051)	\$ (25,300)	\$ (8,268)
Income tax expense	\$ 8,829	\$ 8,965	\$ 27,735	\$ 28,041
Effective income tax rate	59.4 %	127.1 %	109.6 %	339.2 %

The Company has computed its provision for income taxes based on the actual effective rate for the three and nine months ended September 30, 2025 and 2024 as the Company believes this is the best estimate for the annual effective tax rate. Therefore, the Company's effective income tax rates for the three and nine months ended September 30, 2025 and 2024 are not indicative of the effective income tax rate for each respective fiscal year of 2025 and 2024. The Company's effective income tax rate is significantly higher than the statutory income tax rates due in part to (i) an increase in the uncertain tax position liability due to tax positions based on legal interpretations that challenge the Company's tax liability under Internal Revenue Code Section 280E ("280E"), (ii) interest and penalties accrual for tax liabilities, and (iii) state income taxes.

The IRS has taken the position that cannabis companies are subject to the limitation of 280E, a position held by state tax regulators in Nevada, Ohio and Virginia. Under the IRS's interpretation of 280E, cannabis companies are only allowed to deduct expenses directly and indirectly related to the production of inventory.

In connection with the preparation and filing of the fiscal 2022 income tax return, the Company changed its previous application of 280E to exclude certain parts of its business. In regards to fiscal years 2023, 2024, and 2025 tax years, the Company has taken the position that it does not owe taxes attributable to the application of 280E. However, since the Company's tax positions on 280E may be challenged by taxing authorities, the Company elected to treat the deductibility of these related expenses as an uncertain tax position.



The Company has a liability for unrecognized tax benefits of \$171,180 and \$143,688 as of September 30, 2025 and December 31, 2024, respectively. These amounts include interest and penalties of \$36,271 and \$27,839, respectively. The Company anticipates that it is reasonably possible that its new tax position on 280E may require changes to the balance of unrecognized tax benefits within the next 12 months. However, an estimate of such changes cannot reasonably be made.

The total amount of interest and penalties related to the liability for unrecognized tax benefits recorded in income tax expense during the three and nine months ended September 30, 2025 was \$2,397 and \$8,433, respectively. The total amount of interest and penalties related to the liability for unrecognized tax benefits recorded in income tax expense during the three and nine months ended September 30, 2024 was \$2,618 and \$7,070, respectively.

On July 4, 2025, the One Big Beautiful Bill Act was signed into law. The legislation included provisions affecting the limitation on interest deductions and bonus depreciation. The enactment did not have a material impact on the Company's income tax expense for the three and nine months ended September 30, 2025, and is not expected to materially affect the Company's effective income tax rate for 2025. The act reduced the amount of cash the Company would have had to pay for income taxes for the nine months ended September 30, 2025 by \$914.

15. RELATED PARTY TRANSACTIONS

The Company had the following related party transactions:

Nature of transaction	Three Months Ended September 30,		Nine Months Ended September 30,		As of	
	2025	2024	2025	2024	September 30, 2025 (unaudited)	December 31, 2024
	Related Party Expense		Related Party Expense		Related Party Payable	
12% Second Lien Notes - interest expense and principal amount ⁽¹⁾	\$ (769)	\$ (608)	\$ (2,216)	\$ (1,760)	\$ (25,667)	\$ (20,096)
Term Loans - interest expense and principal amount ⁽²⁾	\$ (486)	\$ (328)	\$ (1,458)	\$ (328)	\$ (15,600)	\$ (16,000)

⁽¹⁾ The Second Lien Notes payable and the related interest expense include amounts related to the Company's Chief Executive Officer, as well as a significant investor. In February 2025, an entity affiliated with the Company's Chief Executive Officer, as well as a significant investor, each purchased additional Second Lien Notes in the principal amount of US\$3,719 and C\$2,000 respectively, and also received 5,810,938 warrants and 2,199,688 warrants, respectively. Refer to Note 8 - Debt for more information.

⁽²⁾ The Term Loans payable and the related interest expense include amounts related to the Company's Chief Executive Officer, as well as a significant investor, who each participated as Term Loan lenders in the Company's senior secured term loan refinancing completed in July 2024 in the principal amounts of \$9,000 and \$7,000 respectively, and also received 3,600,000 warrants and 2,800,000 warrants, respectively. Refer to Note 8 - Debt for more information.

16. COMMITMENTS AND CONTINGENCIES

Contingencies

Although the possession, cultivation and distribution of cannabis for medical and recreational use is permitted in certain states, cannabis is classified as a Schedule I controlled substance under the U.S. Controlled Substances Act and its use remains a violation of federal law. The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management believes that the Company is in material compliance with applicable local and state regulations as of September 30, 2025, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company could be subject to regulatory fines, penalties or



restrictions at any time. Since federal law criminalizing the use of cannabis preempts state laws that legalize its use, strict enforcement of federal law regarding cannabis would likely result in the Company's inability to proceed with the Company's business plans. A change in administration due to the recent United States presidential election presents a risk of a change in federal policy. In addition, the Company's assets, including real property, cash and cash equivalents, equipment, inventory and other goods, could be subject to asset forfeiture because cannabis is still federally illegal.

Refer to Note 14 - Income Taxes for certain tax-related contingencies.

Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 30, 2025, except as set forth below, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company's financial results. There are also no proceedings in which any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

MJ's Market Matter

On March 31, 2023, MJ's Market, Inc. ("MJ's") filed a complaint in federal district court in Massachusetts adverse to Jushi Holdings Inc. and certain of its subsidiaries, including Jushi MA, Inc., Jushi Inc. and Nature's Remedy as well as the former owners and affiliates of Nature's Remedy (the "Complaint"). The Complaint centrally claims that the structure of the Nature's Remedy transaction providing for increased purchase price consideration if there is no competing dispensary within 2,500 foot radius by certain time periods, and the Company's filing with the Massachusetts Superior Court an appeal of the Town of Tyngsborough's decision to approve MJ's facility in contradiction of its own zoning bylaws are violations of the Sherman Antitrust Act, Massachusetts Antitrust Act, and Massachusetts Consumer Protection Act, as well as interference with contractual relations and abuse of process. MJ is seeking legal and equitable remedies including compensatory and other damages. On February 5, 2025, the court denied the defendants' motion to dismiss, and the parties to the Complaint are in discovery. The Company disputes such allegations, believes it has substantial defenses and is vigorously defending against the Complaint.

Sammartino Matter

On February 28, 2023, the Company informed Sammartino, the former owner of Nature's Remedy and certain of its affiliates, that Sammartino had breached several provisions of the Merger and Membership Interest Purchase Agreement between the Company, Sammartino and certain other parties thereto (as amended, the "MIPA") and/or fraudulently induced the Company to enter into, and not terminate, the MIPA. As a consequence of these breaches and the fraudulent inducement, the Company informed Sammartino that the Company had incurred significant damages, and pursuant to the terms of the MIPA the Company had elected to offset these damages against certain promissory notes and shares the Company was to pay and issue, respectively, to Sammartino, and that Sammartino would be required to pay the remainder in cash. On March 13, 2023, Sammartino responded to the Company by alleging various procedural deficiencies with the Company's claim and provided the Company with a notice that the Company was in default of the MIPA for failing to issue certain shares of the Company to Sammartino. On March 21, 2023, Sammartino sent a second notice that the Company was in default of the promissory notes for failing to pay interest pursuant to their specified schedule. On March 23, 2023, the Company sent a second letter to Sammartino disputing each procedural deficiency claimed by Sammartino and disputing that the Company is in default of the MIPA or the promissory notes and that it properly followed the terms of the various agreements in electing to set off the damages.

Pacific Collective Matter

On October 24, 2022, Pacific Collective, LLC ("Pacific Collective") filed a complaint in state court in California against Jushi subsidiaries TGS CC Ventures, LLC ("TGS"), and Jushi Inc. Pacific Collective alleges that the Jushi subsidiaries breached a commercial property lease and lease guaranty and that Pacific Collective is entitled to recover in excess of \$20,000 in damages. TGS believes it lawfully rescinded the lease based on Pacific Collective's failure to purchase the

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)*

property that was the subject of the lease and to construct and deliver the building contemplated by the lease and is of the position that no damages are owed to Pacific Collective. The Referee assigned to the matter ruled in favor of and awarded fees and costs to TGS and Jushi. Pacific Collective filed an appeal on July 3, 2024.

Commitments

In addition to the contractual obligations outlined in Note 8 - Debt, the Company has commitments as of September 30, 2025 related to property and construction.

In connection with various license applications, the Company may enter into conditional leases or other property commitments which will be executed if the Company is successful in obtaining the applicable license and/or resolving other contingencies related to the license or application.

In addition, the Company expects to incur capital expenditures for leasehold improvements and construction of buildouts of certain locations, including for properties for which the lease is conditional on obtaining the applicable related license or for which other contingencies exist.

17. FINANCIAL INSTRUMENTS

The following table sets forth the Company's financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy:

	September 30, 2025 (unaudited)	December 31, 2024
Financial liabilities: ⁽¹⁾		
Derivative liabilities ⁽²⁾	\$ 9,395	\$ 3,128
Contingent consideration liabilities ⁽³⁾	—	5,912
Total financial liabilities	<u>\$ 9,395</u>	<u>\$ 9,040</u>

⁽¹⁾ The Company has no financial assets or liabilities in Level 1 or 2 within the fair value hierarchy as of September 30, 2025 and December 31, 2024, and there were no transfers between hierarchy levels during the nine months ended September 30, 2025 or year ended December 31, 2024.

⁽²⁾ Refer to Note 9 - Derivative Liabilities.

⁽³⁾ This was related to the acquisitions of Statewide and RJK. During the nine months ended September 30, 2025, the balance was reclassified to debt as of the second closing for both acquisitions. Refer to Note 8 - Debt for more information.

The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and certain accrued expenses, and certain other assets and liabilities held at amortized cost, approximate their fair values due to the short-term nature of these instruments. The carrying amounts of the promissory notes approximate their fair values as the effective interest rates are consistent with market rates. The carrying amount of the Second Lien Notes approximates their fair values as of September 30, 2025 and December 31, 2024, respectively.

18. SEGMENT INFORMATION

The Company operates a vertically integrated cannabis business in one reportable segment for the cultivation, manufacturing, distribution and sale of cannabis in the U.S. All of the Company's revenues were generated within the U.S., and substantially all long-lived assets are located within the U.S. The accounting policies for the Company's reportable segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker is the Chief Executive Officer. The chief operating decision maker assesses performance and decides how to allocate resources based on operating results that are reported on the income statement as consolidated net income/(loss). The measure of segment assets is reported on the balance sheet as total consolidated assets. Refer to Note 13 - Operating Expenses for significant expenses for the reportable segment.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

This Management's Discussion and Analysis ("MD&A") covers the consolidated financial statements of Jushi Holdings Inc. and its controlled subsidiaries as of and for the three and nine months ended September 30, 2025 (the "Financial Statements"). Unless the context indicates or requires otherwise, the terms "Jushi", "the Company", "we", "us" and "our" refers to Jushi Holdings Inc. and its controlled entities. This MD&A should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto for the three and nine months ended September 30, 2025 (the "Quarterly Financial Statements"). The Quarterly Financial Statements have been prepared by management and are in accordance with generally accepted accounting principles in the United States ("GAAP") and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024, which are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission ("SEC") on March 6, 2025 (the "2024 Form 10-K") and also filed on the System for Electronic Document Analysis and Retrieval ("SEDAR") on March 6, 2025. All amounts are expressed in U.S. dollars unless otherwise noted.

Company Overview

We are a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing operations in both medical and adult-use markets. We are focused on building a diverse portfolio of cannabis assets through opportunistic investments and pursuing application opportunities in attractive limited license jurisdictions and capitalizing on such assets through strategic deployment in our day-to-day operations. We have targeted assets in highly populated, limited license medical markets on a trajectory toward adult-use legalization, including Pennsylvania, markets that are in the process of transitioning to adult-use, namely Virginia, and limited license, fast-growing, large adult-use markets, such as Illinois, Nevada, Massachusetts and Ohio, and certain municipalities of California.

Factors Affecting our Performance and Related Trends

Competition and Pricing Pressure

The cannabis industry is subject to significant competition and pricing pressures, which is often market specific and can be caused by an oversupply of cannabis in the market, and may be transitory from period to period. We may experience significant competitive pricing pressures as well as competitive products and service providers in the markets in which we operate. Several significant competitors may offer products and/or services with prices that may match or are lower than ours. We believe that the products and services we offer are generally competitive with those offered by other cannabis companies. It is possible that one or more of our competitors could develop a significant research advantage over us that allows them to provide superior products or pricing, which could put us at a competitive disadvantage. Continued pricing pressure due to competition, increased cannabis supply or shifts in customer preferences could adversely impact our customer base or pricing structure, resulting in a material impact on our results of operations, or asset impairments in future periods.

Recent Developments

(Amounts expressed in thousands of U.S. dollars)

FVC Loan Modification

In September 2025, we executed a modification agreement (the "Modification Agreement") related to our Manassas mortgage loan agreement "Manassas Mortgage", pursuant to which: (i) the outstanding principal balance was increased by \$4,000, (the "Additional Loan Proceeds"); (ii) the loan's maturity date was extended to September 2030; and (iii) the interest rate floor was lowered from 8.25% to 7.50% (but does not change the interest rate, which remains the average 30-day secured overnight financing rate plus 3.55%). The Manassas Mortgage, as modified, remains principally secured by our cultivation and manufacturing facility located in Manassas, Virginia (the "Property"). In addition, the Modification Agreement requires that \$761 of the Additional Loan Proceeds be deposited into a restricted account, designated for use in fulfilling certain conditions associated with ongoing construction at the Property.

Ohio

In the fourth quarter of 2024, we executed two definitive agreements to purchase assets in the state of Ohio for four dispensary licenses, and related management services agreements. The management services agreements allowed us to consolidate two co-located medical and adult-use dispensaries beginning in the fourth quarter of 2024, and two additional co-located dispensaries during 2025. During the nine months ended September 30, 2025, ownership of the four dispensary licenses were transferred to us.

Results of Operations

(Amounts expressed in thousands of U.S. dollars, except share and per share amounts)

	Three Months Ended September 30,					Nine Months Ended September 30,				
	2025		2024		2025 vs. 2024	2025		2024		2025 vs. 2024
	Amount	% of Revenue	Amount	% of Revenue	\$ Change	Amount	% of Revenue	Amount	% of Revenue	\$ Change
REVENUE, NET	\$ 65,679	100%	\$ 61,611	100%	\$ 4,068	\$ 194,571	100%	\$ 191,665	100%	\$ 2,906
COST OF GOODS SOLD	(35,015)	(53)%	(33,612)	(55)%	(1,403)	(109,208)	(56)%	(98,770)	(52)%	(10,438)
GROSS PROFIT	30,664	47%	27,999	45%	2,665	85,363	44%	92,895	48%	(7,532)
OPERATING EXPENSES	28,326	43%	27,819	45%	507	81,294	42%	80,192	42%	1,102
INCOME FROM OPERATIONS	2,338	4%	180	—%	2,158	4,069	2%	12,703	7%	(8,634)
OTHER INCOME (EXPENSE):										
Interest expense, net	(10,267)	(16)%	(9,382)	(15)%	(885)	(30,486)	(16)%	(27,997)	(15)%	(2,489)
Fair value gain (loss) on derivatives	(6,325)	(10)%	2,628	4%	(8,953)	(5,875)	(3)%	2,840	1%	(8,715)
Other, net	(606)	(1)%	(477)	(1)%	(129)	6,992	4%	4,186	2%	2,806
Total other income (expense), net	(17,198)	(26)%	(7,231)	(12)%	(9,967)	(29,369)	(15)%	(20,971)	(11)%	(8,398)
LOSS BEFORE INCOME TAX	(14,860)	(23)%	(7,051)	(11)%	(7,809)	(25,300)	(13)%	(8,268)	(4)%	(17,032)
Income tax expense	(8,829)	(13)%	(8,965)	(15)%	136	(27,735)	(14)%	(28,041)	(15)%	306
NET LOSS	\$ (23,689)	(36)%	\$ (16,016)	(26)%	(7,673)	\$ (53,035)	(27)%	\$ (36,309)	(19)%	(16,726)
LOSS PER SHARE - BASIC AND DILUTED	\$ (0.12)		\$ (0.08)		\$ (0.04)	\$ (0.27)		\$ (0.19)		\$ (0.08)
Weighted average shares outstanding - basic and diluted	195,196,597		195,165,913		30,684	195,196,597		195,145,417		51,180

Three Months Ended September 30, 2025 Compared with the Three Months Ended September 30, 2024

(Amounts expressed in thousands of U.S. dollars, unless otherwise stated)

Revenue, Net

The following table presents revenue by type for the periods indicated:

	Three Months Ended September 30,		\$ Change	% Change
	2025	2024		
Retail	\$ 58,774	\$ 55,441	\$ 3,333	6 %
Wholesale	6,905	6,170	735	12 %
Total revenue, net	\$ 65,679	\$ 61,611	\$ 4,068	7 %

Total revenue, net, was \$65,679 compared to \$61,611, an increase of \$4,068 or 7%.

Retail revenue increased \$3,333. While the overall units sold in our retail channel increased by approximately 7%, the average price per unit declined. The increase in retail revenue was primarily due to:

- An increase in sales in Ohio of \$3,882 due to the opening of five new dispensaries since the prior year, including the newest co-located medical and adult-use location in Parma which is currently operating under a management services agreement pending regulatory approvals of ownership transfer to the Company; and
- An increase in sales in Virginia of \$1,519 primarily due to an increase in the number of units sold by approximately 7% as certain dispensaries continue to ramp-up, as well as an increase in the average price per unit driven by a shift in sales mix toward higher-priced product offerings.

These increases in retail revenue were partially offset by:

- A decline in sales in Illinois of \$851 - while the number of units sold remained relatively flat, the average price per unit declined as we increased our use of promotions due to continued competition;
- A decline in sales in Nevada of \$531 - while the number of units sold remained relatively flat, the average price per unit declined as we increased our use of promotions due to continued competition; and
- A decline in sales in Massachusetts of \$982 - while the number of units sold decreased by approximately 12% due to continued competition, the average price per unit remained relatively flat.

Additionally, while retail revenue in Pennsylvania remained relatively flat, the number of units sold increased by approximately 5% driven primarily by the opening of one new dispensary in February 2025. However, the average price per unit declined due to increased competition and price compression.

Including the Parma, Ohio store that is currently being operated under a management services agreement, we ended the quarter with forty-one operating dispensaries in seven states, as compared to thirty-five in seven states on September 30, 2024.

Wholesale revenue increased \$735, which was attributable to higher wholesale revenue of \$521 in Massachusetts and \$406 in Pennsylvania, as the prior year was impacted by limited availability of products available to third parties as we prioritized supplying our retail stores in these two states. Additionally, increased production capacity in Ohio contributed to higher wholesale revenue of \$626. These increases were partially offset by a decline of \$1,007 in Virginia due to lower demand from our wholesale partners.

Gross Profit

Gross profit was \$30,664 compared to \$27,999, an increase of \$2,665 or 10%. Gross profit margin increased to 47% compared to 45%. The increase in gross profit and gross profit margin were driven by higher production volumes, improved product quality and stronger performance at our grower-processor facilities, particularly in Massachusetts and

Ohio. In addition, Ohio benefited from higher gross profit and gross profit margin resulting from new dispensary openings and lower costs following the ramping up of our grower processor facility in 2024 to support the transition to adult-use. Jushi branded product sales as a percentage of total retail revenue were 56% across the Company's five vertical markets compared to 55% in the prior year.

Operating Expenses

Operating expenses were \$28,326 compared to \$27,819, an increase of \$507 or 2%. The following table presents information on our operating expenses for the periods indicated:

	Three Months Ended September 30,		\$ Change	% Change
	2025	2024		
Salaries, wages and employee related expenses	\$ 14,315	\$ 14,498	\$ (183)	(1)%
Depreciation and amortization expenses	4,512	3,985	527	13 %
Rent and related expenses	3,184	3,053	131	4 %
Professional fees and legal expenses	1,804	1,320	484	37 %
Share-based compensation expense	357	1,082	(725)	(67)%
Loss on asset disposals and lease terminations	306	443	(137)	(31)%
Other expenses ⁽¹⁾	3,848	3,438	410	12 %
Total operating expenses	\$ 28,326	\$ 27,819	\$ 507	2 %

⁽¹⁾ Other expenses are primarily comprised of marketing and selling expenses, insurance costs, administrative and licensing fees, software and technology costs, travel, entertainment and other.

The increase is primarily driven by higher depreciation and amortization expense resulting from higher operating expenses relating to new dispensary openings and manufacturing facility build-outs, as well as an increase in professional and legal fees. These increases were partially offset by lower share-based compensation expense which reflects higher forfeitures as well as lower value of share-based compensation granted.

Other Income (Expense)

Interest Expense, Net

Interest expense, net was \$10,267 compared to \$9,382, an increase of \$885, or 9%. The increase in interest expense, net is primarily due to the \$48,500 in secured term loans (the "Term Loans") which were issued in July 2024, which was partially offset by the decrease in interest expense from the repayment of the Company's previous secured credit facility (the "Acquisition Facility") in July 2024.

Fair Value gain (loss) on Derivatives

Fair value loss on derivatives was \$6,325, compared to a gain of \$2,628. Fair value gain (loss) on derivatives include the fair value changes relating to the derivative warrants. The derivative warrants are required to be remeasured at fair value at each reporting period. The fair value changes in derivatives were primarily attributable to the movement in our stock price during the corresponding period.

Other, Net

Other, net was an expense of \$606, compared to \$477, a change of \$129.

Income Tax Expense

Total income tax expense was \$8,829 compared to \$8,965 in the prior year, a decrease of \$136 or 2%.

Nine Months Ended September 30, 2025 Compared with the Nine Months Ended September 30, 2024

(Amounts expressed in thousands of U.S. dollars, unless otherwise stated)

Revenue, Net

The following table presents revenue by type for the periods indicated:

	Nine Months Ended September 30,		\$ Change	% Change
	2025	2024		
Retail	\$ 175,058	\$ 169,802	\$ 5,256	3 %
Wholesale	19,513	21,863	(2,350)	(11)%
Total revenue, net	\$ 194,571	\$ 191,665	\$ 2,906	2 %

Revenue, net, was \$194,571 compared to \$191,665, an increase of \$2,906 or 2%.

Retail revenue increased \$5,256. While the overall units sold in our retail channel increased by approximately 7%, average price per unit declined. The increase in retail revenue was primarily due to:

- An increase in sales in Virginia of \$4,653 - while the average price per unit remained relatively flat, the number of units sold increased by approximately 16% as certain dispensaries continue to ramp-up; and
- An increase in sales in Ohio of \$10,509 driven primarily by the opening of five new dispensaries since the prior year, as well as the transition to adult-use during the third quarter of 2024. Beginning in the fourth quarter of 2024, our entry into management services agreement allowed us to consolidate two co-located medical and adult-use dispensaries in Ohio. These dispensaries were acquired by us in February 2025. Furthermore, we consolidated a third dispensary which opened in February 2025, and a fourth dispensary which opened in April 2025 as a result of our gaining control through the management services agreements previously entered into. The third and fourth dispensaries were acquired by us in June 2025 and August 2025, respectively. The addition of the fifth dispensary opened in September 2025 and is operating under a management services agreement pending regulatory approvals of ownership transfer to the Company.

These increases were partially offset by:

- A decline in sales in Illinois of \$4,434 - the number of units sold decreased by approximately 10% and the average price per unit declined due to continued competition;
- A decline in sales in Massachusetts of \$3,042 - the number of units sold decreased by approximately 8% and the average price per unit declined due to continued competition and price compression; and
- A decline in sales in Nevada of \$2,050 - the number of units sold decreased by approximately 3% driven in part by the closure of one dispensary in May 2025, and the average price per unit declined as we increased our use of promotions due to continued competition.

Additionally, while retail revenue in Pennsylvania remained relatively flat, the number of units sold increased by approximately 13% driven in part by the opening of one new dispensary in February 2025. However, the average price per unit declined due to increased competition and price compression.

Wholesale revenue decreased \$2,350. The decrease is primarily attributable to a decline of \$2,818 in Virginia due to limited availability of products for third parties through our wholesale channel as we prioritized supplying our own retail stores during the first half of 2025, and a decline of \$1,286 in Massachusetts due to lower bulk cannabis flower sales. These decreases were partially offset by an increase of \$1,213 in Ohio due to the transition to adult-use during the third quarter of 2024, as well as increased production capacity.

Gross Profit

Gross profit was \$85,363 compared to \$92,895, a decrease of \$7,532 or 8%. Gross profit margin decreased to 44% compared to 48%. The decrease in gross profit and gross profit margin was driven by continued competitive pricing pressure requiring higher discounting in our retail channel. In addition, higher production costs per unit from prior periods are being reflected in the current year's cost of sales as products produced in prior periods turn. These decreases were partially offset by higher gross profit and gross profit margin in Ohio as a result of new dispensary openings, as well as lower costs following the ramping up our grower processor facility in 2024 to support the transition to adult-use. Jushi branded product sales as a percentage of total retail revenue were 56% across the Company's five vertical markets compared to 55% in the prior year.

Operating Expenses

Operating expenses were \$81,294 compared to \$80,192, an increase of \$1,102 or 1%. The following table presents information on our operating expenses for the periods indicated:

	Nine Months Ended September 30,		\$ Change	% Change
	2025	2024		
Salaries, wages and employee related expenses	\$ 43,055	\$ 42,837	\$ 218	1 %
Depreciation and amortization expenses	13,702	11,090	2,612	24 %
Rent and related expenses	9,415	8,928	487	5 %
Professional fees and legal expenses	5,584	5,501	83	2 %
Share-based compensation expense	424	2,953	(2,529)	(86)%
Gain on asset disposals and lease terminations	(2,992)	(2,233)	(759)	34 %
Other expenses ⁽¹⁾	12,106	11,116	990	9 %
Total operating expenses	\$ 81,294	\$ 80,192	\$ 1,102	1 %

⁽¹⁾ Other expenses are primarily comprised of marketing and selling expenses, insurance costs, administrative and licensing fees, software and technology costs, travel, entertainment and other.

The increase is primarily driven by higher depreciation and amortization expense due to the amortization of our business licenses which commenced on June 1, 2024, as we concluded that our business licenses no longer have indefinite useful lives. This was partially offset by lower share-based compensation expense which reflects higher forfeitures as well as lower value of share-based compensation granted.

Other Income (Expense)

Interest Expense, Net

Interest expense, net was \$30,486 compared to \$27,997, an increase of \$2,489, or 9%. The increase in interest expense, net is primarily due to the Term Loans which were issued in July 2024, which was partially offset by the decrease in interest expense from the repayment of the Acquisition Facility in July 2024.

Fair Value gain (loss) on Derivatives

Fair value loss on derivatives was \$5,875, compared to a gain of \$2,840. Fair value gain (loss) on derivatives include the fair value changes relating to the derivative warrants. The derivative warrants are required to be remeasured at fair value at each reporting period. The fair value changes in derivatives were primarily attributable to the movement in our stock price during the corresponding period.

Other, Net

Other, net was an income of \$6,992, compared to \$4,186, an increase of \$2,806. The current period is primarily comprised of \$7,621 related to employee retention credit claims, including interest, received from the IRS, and \$914 gain on sale of a non-core asset, partially offset by \$1,671 indemnification asset adjustment related to acquisitions made in prior years and

\$568 foreign exchange translation loss in relation to certain Second Lien Notes denominated in Canadian dollars. The prior year is primarily comprised of \$1,896 gain on Jushi Europe deconsolidation, \$457 foreign exchange translation gain in relation to certain Second Lien Notes denominated in Canadian dollars, \$455 indemnification asset adjustment related to acquisitions made in prior years, and \$400 reversal of legal claim accruals no longer required.

Income Tax Expense

Total income tax expense was \$27,735 compared to \$28,041 in the prior year, a decrease of \$306 or 1%.

Non-GAAP Measures and Reconciliation

In addition to providing financial measurements based on GAAP, we provide additional financial metrics that are not prepared in accordance with GAAP. We use non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate our financial performance. These non-GAAP financial measures are EBITDA and Adjusted EBITDA (each as defined below). We believe that these non-GAAP financial measures reflect our ongoing business by excluding the effects of expenses that are not reflective of our operating business performance and allow for meaningful comparisons and analysis of trends in our business. These non-GAAP financial measures also facilitate comparing financial results across accounting periods and to those of peer companies. As there are no standardized methods of calculating these non-GAAP measures, our methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness. Accordingly, these non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

EBITDA and Adjusted EBITDA

EBITDA and Adjusted EBITDA are financial measures that are not defined under GAAP. We define EBITDA as net income (loss), or “earnings”, before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA before: (i) non-cash share-based compensation expense; (ii) inventory-related adjustments; (iii) fair value changes in derivatives; (iv) other (income)/expense items; (v) transaction costs; (vi) asset impairment; and (vii) gain/loss on debt extinguishment. These financial measures are metrics that have been adjusted from the GAAP net income (loss) measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. Other companies in our industry may calculate this measure differently, limiting their usefulness as comparative measures.

Reconciliation of EBITDA and Adjusted EBITDA (Non- GAAP Measures)

Adjusted EBITDA for the three months ended September 30, 2025 and 2024, was \$12,793 and \$10,345, respectively, an increase of \$2,448 or 24%. The increase was due primarily to higher margin resulting from stronger performance at our grower processor facilities, and new dispensary openings.

Adjusted EBITDA for the nine months ended September 30, 2025 and 2024, was \$36,335 and \$38,172, respectively, a decrease of \$1,837 or 5%. The decrease was primarily due to overall lower margin, which was partially offset by payments received from the IRS in relation to employee retention credit claims.

[Table of Contents](#)

The table below reconciles net loss to EBITDA and Adjusted EBITDA for the periods indicated.

(Amounts expressed in thousands of U.S. dollars)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
NET LOSS	\$ (23,689)	\$ (16,016)	\$ (53,035)	\$ (36,309)
Income tax expense	8,829	8,965	27,735	28,041
Interest expense, net	10,267	9,382	30,486	27,997
Depreciation and amortization ⁽¹⁾	7,796	7,768	23,798	21,981
EBITDA (Non-GAAP)	3,203	10,099	28,984	41,710
Non-cash share-based compensation	357	1,082	424	2,953
Fair value changes in derivatives	6,325	(2,628)	5,875	(2,840)
Tangible long-lived asset impairment	—	275	—	432
Other (income) expense, net ⁽²⁾	2,908	756	1,052	(2,549)
Loss on debt extinguishment	—	761	—	362
Gain on deconsolidation of Jushi Europe	—	—	—	(1,896)
Adjusted EBITDA (Non-GAAP)	\$ 12,793	\$ 10,345	\$ 36,335	\$ 38,172

⁽¹⁾ Includes amounts that are included in cost of goods sold and in operating expenses.

⁽²⁾ Includes: (i) remeasurement of contingent consideration related to acquisitions; (ii) losses (gains) on legal settlements; (iii) losses (gains) on asset disposals; (iv) foreign exchange losses (gains); (v) indemnification asset adjustments related to acquisitions; and (vi) start-up costs.

Liquidity and Capital Resources

(Amounts expressed in thousands of U.S. dollars, unless otherwise stated)

Sources and Uses of Cash

We had cash, cash equivalents and restricted cash of \$26,159 as of September 30, 2025.

The major components of our statements of cash flows for the nine months ended September 30, 2025 and 2024, are as follows:

	Nine Months Ended September 30,		\$ Change	% Change
	2025	2024		
Net cash flows provided by operating activities	\$ 11,674	\$ 14,415	\$ (2,741)	(19)%
Net cash flows (used in) provided by investing activities	(10,152)	189	(10,341)	(5471)%
Net cash flows provided by (used in) financing activities	3,291	(23,018)	26,309	114 %
Net change in cash, cash equivalents and restricted cash	\$ 4,813	\$ (8,414)	\$ 13,227	(157)%

Operating activities

Cash provided by operations was \$11,674, as compared to \$14,415. The decrease was primarily due to a decline in our operating results.

Investing activities

Net cash used in investing activities was \$10,152 compared to net cash provided by investing activities of \$189. The current year includes \$13,003 for the purchase of property, plant and equipment for use in our operations, and \$1,099 of intangible assets acquired, which were partially offset by \$3,950 proceeds from sale of non-core assets. The prior year

includes \$2,534 for the purchase of property, plant and equipment for use in our operations, which was more than offset by \$2,723 in proceeds from the sale of non-core assets.

Financing activities

Net cash provided by financing activities was \$3,291 compared to net cash used in financing activities of \$23,018.

The current year cash flows provided by financing activities includes \$4,608 net proceeds from Second Lien Notes and \$3,473 net mortgage loan proceeds, which were partially offset by \$1,768 in net finance lease obligation payments, \$1,365 in payments of other financing activities, \$1,213 Term Loan payments, and \$444 in payments of mortgage-related debt.

The prior year net cash flows used in financing activities includes \$60,125 payments related to the Acquisition Facility which was extinguished in July 2024, and \$12,047 in other payments. These payments were partially offset by \$47,530 of net proceeds from the issuance of Term Loans and \$1,624 of proceeds from other financing activities.

Liquidity

As of September 30, 2025, our Term Loans with a principal balance of \$47,288 are scheduled to mature within the next twelve months. The Term Loans' upcoming maturity raises substantial doubt about our ability to continue as a going concern without refinancing. Given our plan to refinance before maturity and our consistent history of successful refinancing, substantial doubt has been alleviated. We believe that our existing cash and cash equivalents, cash from operations and from refinancing will be sufficient to meet our working capital and capital expenditure needs for at least the next twelve months.

During the nine months ended September 30, 2025, we enhanced liquidity by factoring certain employee retention credit claims, issuing Second Lien Notes, and increasing the principal balance on one of our mortgage loans - refer to Note 4 - Prepaid Expenses and Other Current Assets and Note 8 - Debt of our Quarterly Financial Statements contained in Part I. Item 1 of this report for more information. We may choose to take advantage of additional opportunistic capital raising or refinancing transactions at any time. Depending on our future results of operations, we may need to engage in additional equity financing or other debt refinancing transactions in the longer term beyond twelve months, although there can be no assurances that such additional debt or equity financing may be obtained on favorable terms when required, if at all.

Off-Balance Sheet Arrangements and Contractual Obligations

As of September 30, 2025, we do not have any off-balance sheet arrangements. For our contractual obligations, refer to Note 8 - Debt and Note 16 - Commitments and Contingencies of our Quarterly Financial Statements contained in Part I. Item 1 of this report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to the risks disclosed in Item 7A of our 2024 Form 10-K.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management carried out an evaluation under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2025, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

For a description of our legal proceedings, refer to Claims and Litigation in Note 16 - Commitments and Contingencies in the Notes to the Unaudited Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

The Company is subject to numerous risks and uncertainties, any of which could have a significant or material adverse effect on our business, financial condition, liquidity or consolidated financial statements. You should carefully consider the risk factors disclosed under the heading “Risk Factors”, which are included in the 2024 Form 10-K, which was also filed on SEDAR. The risks described therein and herein are not the only ones we face. Other than set forth herein, there have been no material changes from the risk factors previously disclosed.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

On August 13, 2025, an affiliate of the Company entered a Seventh Amendment to Lease Agreement, by and between IIP-PA 1, LLC and Pennsylvania Medical Solutions, LLC. The amendment makes certain non-material changes to the underlying lease agreement. A copy of the amendment is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q.

Insider trading arrangements

During the three months ended September 30, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).

Item 6. Exhibits

10.1	Seventh Amendment to Lease Agreement, by and between by and between IIP-PA 1, LLC and Pennsylvania Medical Solutions, LLC dated August 13, 2025
10.2 ^(a)	Allonge and Modification Agreement, dated September 18, 2025, by and among Dalitso LLC, JREHVA, LLC, Jushi VA, LLC, Jushi Holdings Inc. and FVCBank.
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)
32.1	Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded with Inline XBRL File)

(a) Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Jushi Holdings Inc. on September 22, 2025.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

JUSHI HOLDINGS INC.

Date: November 4, 2025

By: /s/ Michelle Mosier
Michelle Mosier
Chief Financial Officer and Chief Accounting Officer
(principal financial and accounting officer)

SEVENTH AMENDMENT TO LEASE AGREEMENT

THIS SEVENTH AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is entered into as of this 13th day of August, 2025 (the “Amendment Effective Date”), by and between IIP-PA 1 LLC, a Delaware limited liability company (“Landlord”), and Pennsylvania Medical Solutions, LLC, a Pennsylvania limited liability company (“Tenant”).

RECITALS

A. WHEREAS, Landlord and Tenant are parties to that certain Lease Agreement dated as of April 6, 2018 (the “Original Lease”), as amended by that certain First Amendment to Lease Agreement dated December 7, 2018 (the “First Amendment”), as further amended by that certain Second Amendment to Lease Agreement dated as of January 14, 2020 (the “Second Amendment”), as further amended by that certain Third Amendment to Lease Agreement dated as of April 10, 2020 (the “Third Amendment”), as further amended by that certain Fourth Amendment to Lease Agreement dated as of August 25, 2020 (the “Fourth Amendment”), as further amended by that certain Fifth Amendment to Lease Agreement dated as of April 1, 2021 (the “Fifth Amendment”), and as further amended by that certain Sixth Amendment to Lease Agreement dated as of February 2, 2022 (the “Sixth Amendment”) and together with the Original Lease, the First Amendment, the Second Amendment, the Third Amendment, the Fourth Agreement, and the Fifth Amendment, the “Existing Lease”), whereby Tenant leases the premises from Landlord commonly referred to as 2000 Rosanna Avenue in Scranton, Pennsylvania; and

B. WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.

AGREEMENT

NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows:

1. Definitions. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein. The Existing Lease, as amended by this Amendment, is referred to collectively herein as the “Lease.” From and after the date hereof, the term “Lease,” as used in the Existing Lease, shall mean the Existing Lease, as amended by this Amendment.

2. Replacement Lights. Tenant has requested that Landlord consent to Tenant financing the purchase and installation of certain cultivation lights for the Premises (the “Replacement Lights”) through an equipment lease (“Equipment Lease”) with Xtraction Services, Inc. (“Equipment Lessor”). The Replacement Lights will replace certain existing lights that are owned by Landlord and were installed as part of the Tenant Improvements to be maintained, repaired and replaced by Tenant during the Term of the Lease (the “Existing Lights”). Subject to the terms of this Amendment, Landlord has agreed to consent to the foregoing and to execute and deliver a landlord waiver agreement to Equipment Lessor in the form approved by Landlord. Upon removal of the Existing Lights, Tenant agrees to store and maintain the Existing Lights in good condition, normal wear and tear excepted. Once the Replacement Lights have been paid for in full under the Equipment Lease, Landlord shall be deemed to be the owner of such Replacement Lights and the Replacement Lights and the Existing Lights shall remain part of the Premises. If the Replacement Lights are removed by Tenant or Equipment Lessor, then Tenant shall be required to reinstall the Existing Lights to working order and condition or install new replacement cultivation lights of at least the same quality and otherwise in good working order and condition, subject to and in accordance with the terms of the Lease. Following any termination of the Lease due to an uncured Default by Tenant, upon Landlord’s request, Tenant shall assign to Landlord all rights of Tenant in and to the Equipment Lease with respect to the Replacement Lights.

3. Broker. Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Amendment and agrees to reimburse, indemnify, save, defend (at Landlord’s option and with counsel reasonably acceptable to Landlord, at Tenant’s sole cost and expense) and hold harmless the Landlord Indemnitees for, from and against any and all cost or liability for compensation claimed by any such broker or agent employed or engaged by it or claiming to have been employed or engaged by it.

4. No Default. Tenant represents, warrants and covenants that, to the best of Tenant's knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Existing Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder.

5. Effect of Amendment. Except as modified by this Amendment, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. In the event of any conflict between the terms contained in this Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties.

6. Successors and Assigns. Each of the covenants, conditions and agreements contained in this Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees. Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.

7. Miscellaneous. This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.

8. Authority. Tenant guarantees, warrants and represents that the individual or individuals signing this Amendment have the power, authority and legal capacity to sign this Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.

9. Counterparts; Facsimile and PDF Signatures. This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on this Amendment shall be equivalent to, and have the same force and effect as, an original signature.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment as of the date and year first above written.

LANDLORD:

IIP-PA 1 LLC,
a Delaware limited liability company

By: __ Name: __ Title: __

TENANT:

PENNSYLVANIA MEDICAL SOLUTIONS, LLC,
a Pennsylvania limited liability company

By: __ Name: __ Title: __

**Certification of Chief Executive Officer
pursuant to Rule 13a-14(a) or Rule 15d-14(a)**

I, James Cacioppo, certify that:

- (1) I have reviewed this quarterly report on Form 10-Q of Jushi Holdings Inc.;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- (4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- (5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 4, 2025

/s/ James Cacioppo

James Cacioppo
Chief Executive Officer
(principal executive officer)

**Certification of Chief Financial Officer
pursuant to Rule 13a-14(a) or Rule 15d- 14(a)**

I, Michelle Mosier, certify that:

- (1) I have reviewed this quarterly report on Form 10-Q of Jushi Holdings Inc.;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- (4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- (5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 4, 2025

/s/ Michelle Mosier

Michelle Mosier

Chief Financial Officer and Chief Accounting
Officer
(principal financial and accounting officer)

**Certification of Chief Executive Officer
under Section 906 of the Sarbanes-Oxley Act of 2002
(18 U.S.C. § 1350)**

In connection with the quarterly report of Jushi Holdings Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James Cacioppo, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 4, 2025

/s/ James Cacioppo

James Cacioppo

Chief Executive Officer
(principal executive officer)

The foregoing certification is being furnished as an exhibit to the Report pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 and, accordingly, is not being filed with the Securities and Exchange Commission as part of the Report and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Report, irrespective of any general incorporation language contained in such filing).

**Certification of Chief Financial Officer
under Section 906 of the Sarbanes-Oxley Act of 2002
(18 U.S.C. § 1350)**

In connection with the quarterly report of Jushi Holdings Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Michelle Mosier, Chief Financial Officer and Chief Accounting Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 4, 2025

/s/ Michelle Mosier

Michelle Mosier
Chief Financial Officer and Chief Accounting Officer
(principal financial officer)

The foregoing certification is being furnished as an exhibit to the Report pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 and, accordingly, is not being filed with the Securities and Exchange Commission as part of the Report and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Report, irrespective of any general incorporation language contained in such filing).